Use of angiotensin-converting enzyme inhibitors and diuretics in antihypertensive therapy advised by Polish medical doctors – a final report from questionnaire ALMONDS study Original article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Mar 31, 2016
Keywords:
arterial hypertension, angiotensin-converting enzyme inhibitors, diuretics, guidelines, health care surveys

Main Article Content

Krzysztof J. Filipiak
I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny
Aleksandra Gąsecka
I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny
Marcin Lewandowski
Szkoła Biznesu, Politechnika Warszawska
Anna E. Płatek
I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny
Filip M. Szymański
I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny
Beata Wożakowska-Kapłon
I Klinika Kardiologii i Elektroterapii, Świętokrzyskie Centrum Kardiologii, Uniwersytet im. Jana Kochanowskiego w Kielcach
Andrzej Tykarski
Katedra i Klinika Hipertensjologii, Angiologii i Chorób Wewnętrznych, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu

Abstract

Introduction: Data from clinical trials have demonstrated an improvement in long-term outcomes in subjects at high risk of cardiovascular events treated with ramipril and perindopril, as well as in patients with a history of acute myocardial infarction treated with zofenopril. These observations have revolutionized the position of angiotensin-converting enzyme (ACE) in antihypertensive therapy. Diuretics were commonly seen as medicaments that adversely influenced the metabolism of carbohydrates and lipids. Metabolic neutral and well-tolerated newer drugs within the class have changed this view. However, the observed benefits refer only to particular molecules within the class, thus indicating their superiority over other molecules.


The aim of the study: The aim of the questionnaire ALMONDS study was to identify the attitude of Polish medical professionals towards novel pharmacological agents used in the therapy of arterial hypertension. Especially, we sought to investigate the views regarding the class effect within antihypertensive agents.


Materials and methods: The study was conducted using the standardized survey, which was filled in by 784 medical doctors, who specialize in cardiology, internal medicine, primary health care and diabetology. All participants received the survey by post and remained anonymous, which allowed to maximize the reliability of collected data.


Results: Among ACE inhibitors, zofenopril and ramipril were recognized as particularly beneficial in terms of cardiovascular mortality and morbidity (83.5% of women, 79.1% of men). The most frequently cited clinical trial that demonstrated lack of class effect within ACE inhibitors was SMILE-4 study, which compared zofenopril with ramipril (74.2% of women, 70.5% of men). The majority of study participants declared, that a combination of ACE inhibitors and angiotensin II receptor antagonists is harmful (50.9% of women, 48.8% of men). Among diuretics used in antihypertensive therapy, the majority of study participants chose thiazide-like diuretics (38.7% of women, 41.2% of men). In treatment of refractory hypertension, torasemid and indapamid were most frequently selected (58.2% of women, 55.7% of men and 19.3% of women, 18.1% of men, respectively). Among novel diuretics, the greatest future perspectives were declared for torasemid in different doses (67.2% of women, 61.5% of men). The majority of study participants admitted that torasemid is superior to furosemide within the class of loop diuretics (89.5% of women, 89.2% of men).


Conclusions: The results of the study indicate that Polish medical specialists have clear preferences regarding the choice of specific pharmacological agents within the groups in treatment of hypertension. Among ACE inhibitors, zofenopril and ramipril were preferred, whereas among diuretics, torasemid and indapamid were the most frequently selected. This attitude remains coherent with the Guidelines of Polish Society of Arterial Hypertension, 2015.

Article Details

How to Cite
Filipiak , K. J., Gąsecka, A., Lewandowski , M., Płatek , A. E., Szymański , F. M., Wożakowska-Kapłon, B., & Tykarski , A. (2016). Use of angiotensin-converting enzyme inhibitors and diuretics in antihypertensive therapy advised by Polish medical doctors – a final report from questionnaire ALMONDS study. Medycyna Faktow (J EBM), 9(1(30), 6-17. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2258
Issue
Vol 9 No 1(30) (2016)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Tykarski A., Narkiewicz K., Gaciong Z.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Nadciśnienie Tętnicze w Praktyce 2015; 1: 1-70.
2. Sayer G., Bhat G.: The renin-angiotensin-aldosterone system and heart failure. Cardiol. Clin. 2014; 32: 21-32.
3. Cheng J., Zhang W., Zhang X. et al.: Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern. Med. 2014; 174: 773-785.
4. Molnar M.Z., Kalantar-Zadeh K., Lott E.H.: Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J. Am. Coll. Cardiol. 2014; 63: 650-658.
5. Fox K.M.; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
6. Yusuf S., Sleight P., Pogue J. et al.: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342: 145-153.
7. del Corso F., Pareo I., Borghi C.: Evolving concept of cardioprotection in myocardial infarction: from SMILE-1 to SMILE-5. Kardiol. Pol. 2013; 71(7): 667-674.
8. Shah A.D., Arora A.R.: Tissue Angiotensin-Converting Enzyme Inhibitors: Are They More Effective than Serum Angiotensin-Converting Enzyme Inhibitors? Clin. Cardiol. 2005; 28: 551-555.
9. The Systolic Hypertension in the Elderly Program (SHEP) Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.
10. Filipiak K.J., Gąsecka A., Lewandowski M. et al.: Stosowanie beta-adrenolityków i antagonistów wapnia w leczeniu hipotensyjnym w praktyce polskich lekarzy – raport końcowy z badania ankietowego ALMONDS. Choroby Serca i Naczyń 2016 [ahead of print].
11. Filipiak K.J., Gąsecka A., Lewandowski M. et al.: Postawy polskich lekarzy wobec nowych leków hipotensyjnych – raport końcowy z ankietowego badania ALMONDS. Folia Cardiologica 2016 [ahead of print].
12. Evangelista S., Manzini S.: Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J. Int. Med. Res. 2005; 33: 42-54.
13. Borghi C., Omboni S., Reggiardo G.: Cardioprotective role of zofenopril in patients with acute myocardial infarction: a pooled individual data analysis of four randomised, double-blind, controlled, prospective studies. Open Heart 2015; 2: e000220.
14. Pilote L., Abrahamowicz M., Rodrigues E. et al.: Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Intern. Med. 2004; 141: 102-112.
15. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 1987; 316: 1429-1435.
16. Yusuf S., Teo K.K., Pogue J. et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-1559.
17. Bangalore S., Kumar S., Kjeldsen S.E.: Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 2011; 12: 65-82.
18. Mao Y., Xu X., Wang X. et al.: Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer? Oncotarget 2016 [epub ahead of print].
19. Makar G.A., Holmes J.H., Yang Y.X.: Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J. Natl. Cancer Inst. 2014; 106 [epub ahead of print].
20. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2197.
21. ADVANCE Collaborative Group: Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007; 370: 829-840.
22. Chen P., Chaugai S., Zhao F., Wang D.W.: Cardioprotective Effect of Thiazide-Like Diuretics: A Meta-Analysis. Am. J. Hypertens. 2015; 28: 1453-1463.
23. Brzezinska U., Tykarski A.: Diuretyki w leczeniu hipotensyjnym – nowe doniesienia, stare wątpliwości. Czas na rozsądny wybór? Arterial Hypertension 2005; 9: 474-488.
24. Dyrla W., Kuch M.: Torasemid i furosemid – podobieństwa i różnice. Medycyna Faktów 2014; 7: 7-11.
25. TORIC investigators: Torasemide in chronic heart failure: results of the TORIC study. Eur. J. Heart Fail. 2002; 4: 507-513.
26. Trzaska E., Gumułka W., Makulska-Nowak H.E.: Antagoniści aldosteronu w farmakoterapii chorób układu krążenia. Kardiol. Pol. 2009; 67: 667-671.